Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deborah Thomas

Showing results (41-50 of 155) with videos related to

Pageof 16
Sort By:
Cancer Chemotherapy and Pharmacology|November 27, 2002
Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemiaJorge Cortes, Apostolia M Tsimberidou, Ricardo Alvarez, et al.
ACS Chemical Neuroscience|January 28, 2021
Solvatochromic and pH-Sensitive Fluorescent Membrane Probes for Imaging of Live CellsDeborah Thomas, Vicente Rubio, Vijaya Iragavarapu, et al.
Psychiatric Services (Washington, D.C.)|June 19, 2012
Personal characteristics affecting veterans' use of services for posttraumatic stress disorderElizabeth Brooks, Douglas K Novins, Deborah Thomas, et al.
Cancer Chemotherapy and Pharmacology|August 31, 2002
Recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein Enbrel in patients with refractory hematologic malignanciesApostolia-Maria Tsimberidou, Deborah Thomas, Susan O'Brien, et al.
Cancer|February 22, 2002
Central nervous system relapse in adults with acute lymphoblastic leukemiaUsha R Surapaneni, Jorge E Cortes, Deborah Thomas, et al.
The Oncologist|September 5, 2006
Advances in the therapy of chronic idiopathic myelofibrosisCecilia Arana-Yi, Alfonso Quintás-Cardama, Francis Giles, et al.
Blood|April 17, 2009
Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapyAlfonso Quintás-Cardama, Hagop Kantarjian, Dan Jones, et al.
Leukemia Research|January 18, 2003
Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemiaEfrosyni Apostolidou, Elihu Estey, Jorge Cortes, et al.
Haematologica|August 6, 2002
A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromesGuillermo Garcia-Manero, Stefan Faderl, Francis Giles, et al.
Cancer|March 13, 2009
Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapyAlfonso Quintás-Cardama, Hagop Kantarjian, Farhad Ravandi, et al.
Pageof 16

Showing results (41-50 of 155) with videos related to

Sort By:
Pageof 16
Cancer Chemotherapy and Pharmacology|November 27, 2002
Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemiaJorge Cortes, Apostolia M Tsimberidou, Ricardo Alvarez, et al.
ACS Chemical Neuroscience|January 28, 2021
Solvatochromic and pH-Sensitive Fluorescent Membrane Probes for Imaging of Live CellsDeborah Thomas, Vicente Rubio, Vijaya Iragavarapu, et al.
Psychiatric Services (Washington, D.C.)|June 19, 2012
Personal characteristics affecting veterans' use of services for posttraumatic stress disorderElizabeth Brooks, Douglas K Novins, Deborah Thomas, et al.
Cancer Chemotherapy and Pharmacology|August 31, 2002
Recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein Enbrel in patients with refractory hematologic malignanciesApostolia-Maria Tsimberidou, Deborah Thomas, Susan O'Brien, et al.
Cancer|February 22, 2002
Central nervous system relapse in adults with acute lymphoblastic leukemiaUsha R Surapaneni, Jorge E Cortes, Deborah Thomas, et al.
The Oncologist|September 5, 2006
Advances in the therapy of chronic idiopathic myelofibrosisCecilia Arana-Yi, Alfonso Quintás-Cardama, Francis Giles, et al.
Blood|April 17, 2009
Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapyAlfonso Quintás-Cardama, Hagop Kantarjian, Dan Jones, et al.
Leukemia Research|January 18, 2003
Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemiaEfrosyni Apostolidou, Elihu Estey, Jorge Cortes, et al.
Haematologica|August 6, 2002
A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromesGuillermo Garcia-Manero, Stefan Faderl, Francis Giles, et al.
Cancer|March 13, 2009
Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapyAlfonso Quintás-Cardama, Hagop Kantarjian, Farhad Ravandi, et al.
Pageof 16